<DOC>
	<DOC>NCT01441232</DOC>
	<brief_summary>This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Adults aged 18 to 65 years of age History of Type 2 Diabetes Mellitus for at least 3 months prior to Screening, with HgbA1c values of 6.5 to 10.5% and Cpeptide ≥1.0 ng/mL Body mass index (BMI) ≤45 kg/sq m Willing and able to selfmonitor blood glucose Able to provide written informed consent History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes Current use of any blood glucose lowering agent other than metformin History of renal disease or clinically significant abnormal kidney function tests at Screening or Day 2 Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or Day 2 History of myocardial infarction, severe/unstable angina, or coronary revascularization procedure within 6 months of Day 2 History of clinically significant cardiac arrhythmias within 1 year of Day 2 Congestive heart failure and/or New York Heart Association (NYHA) class III or IV symptoms of heart failure Subjects with uncontrolled Stage 3 hypertension History of 2 or more emergency room visits, doctor's visits, or hospitalizations due to hypoglycemia within 6 months of Day 2 History of alcohol or drug abuse within 12 months of Screening History of bowel resection &gt; 20 cm, any malabsorptive disorder, severe gastroparesis, and GI procedure for the purpose of weight loss that would slow gastric emptying History of HIV or hepatitis C Major surgery within 3 months of Day 2 or any planned surgery during the study History of any active infection within 2 weeks of Day 2 History of pancreatitis History of any malignancy within the last 5 years which would affect the diagnosis or assessment of LX4211 or sitagliptin History of any serious adverse reaction or hypersensitivity to LX4211 or sitagliptin Presence of any clinically significant physical, laboratory, or ECG findings or any concurrent condition at Screening that may interfere with the study in the opinion of the investigator Triglycerides &gt; 1000 mg/dL at Screening or Day 2 Donation or loss of &gt;400 mL of blood or blood product within 8 weeks prior to Day 2 Use of any tobacco product for the duration of study participation Use of corticosteroids within 2 weeks of Day 1 Use of digoxin or warfarin within 2 weeks prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>